Production of α2,6-sialylated IgG1 in CHO cells

mAbs

Volumn 7, Issue 3, 2015, Pages 571-583

  Raymond, Céline ^a,b   Robotham, Anna ^a   Spearman, Maureen ^c   Butler, Michael ^c   Kelly, John ^a   Durocher, Yves ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

B4GALT1; CHO cells; IgG1; N glycosylation; Sialylation; SIAT1; Transfection

Indexed keywords

AGGLUTININ; ALPHA 2,6 SIALYLATED IMMUNOGLOBULIN G1; BETA 1,4 GALACTOSYLTRANSFERASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPSTEIN BARR VIRUS ANTIGEN 1; GALACTOSE; GALACTOSYLTRANSFERASE; GLYCAN DERIVATIVE; GREEN FLUORESCENT PROTEIN; LECTIN; MONOCLONAL ANTIBODY; SIALIDASE; SIALIDASE S; TRASTUZUMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; N ACETYLLACTOSAMINE SYNTHASE; SIALIC ACID DERIVATIVE; SIALYLTRANSFERASE; ST6GAL1 PROTEIN, HUMAN;

ANIMAL CELL; ANTIBODY AND IMMUNOGLOBULIN PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOTTING; CHO CELL LINE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA DETERMINATION; ELECTROSPRAY; ERYTHRINA; ERYTHRINA CRISTAGALLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUTATION; NONHUMAN; OXIDATION; PLASMID; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SAMBUCUS NIGRA; SIALYLATION; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; CRICETULUS; GENETICS; HAMSTER; HUMAN; METABOLISM; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMMUNOGLOBULIN G; MUTATION, MISSENSE; N-ACETYLLACTOSAMINE SYNTHASE; SIALIC ACIDS; SIALYLTRANSFERASES;

EID: 84940644112     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1029215     Document Type: Article

References (66)

1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-16; PMID: 20414204; http://dx. doi. org/10. 1038/nri2761.
2. Albanesi M, Daëron M. The interactions of therapeutic antibodies with Fc receptors. Immunol Lett 2012; 143: 20-7; PMID: 22553779; http://dx. doi. org/10. 1016/j. imlet. 2012. 02. 005.
3. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12: 14; PMID: 22896759.
4. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50; PMID: 17029568; http://dx. doi. org/10. 1146/annurev. immunol. 25. 022106. 141702.
5. Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. CA Hum Antibodies 2010; 19: 89-99.
6. Houde D, Peng Y, Berkowitz SA, Engen JR. Posttranslational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010; 9: 1716-28; http://dx. doi. org/10. 1074/mcp. M900540-MCP200.
7. Leatherbarrow RJ, Rademacher TW, Dwek RA, Woof JM, Clark A, Burton DR, Richardson N, Feinstein A. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol 1985; 22: 407-15; PMID: 4033665; http://dx. doi. org/10. 1016/0161-5890(85)90125-7.
8. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595-601; PMID: 2507634.
9. Wormald MR, Rudd PM, Harvey DJ, Chang S-C, Scragg IG, Dwek RA. Variations in oligosaccharideprotein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36: 1370-80; PMID: 9063885; http://dx. doi. org/10. 1021/bi9621472.
10. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325: 979-89; PMID: 12527303; http://dx. doi. org/10. 1016/S0022-2836(02)01250-0.
11. Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, Trout BL. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PloS One 2009; 4: e8425; PMID: 20037630; http://dx. doi. org/10. 1371/journal. pone. 0008425.
12. Holland M, Yagi H, Takahashi N, Kato K, Savage COS, Goodall DM, Jefferis R. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 2006; 1760: 669-77; PMID: 16413679; http://dx. doi. org/10. 1016/j. bbagen. 2005. 11. 021.
13. Wuhrer M, Stam JC, van de Geijn FE, Koeleman CA, Verrips CT, Dolhain RJEM, Hokke CH, Deelder AM. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 2007; 7: 4070-81; PMID: 17994628; http://dx. doi. org/10. 1002/pmic. 200700289.
14. Anumula KR. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. J Immunol Methods 2012; 382: 167-76; PMID: 22683540; http://dx. doi. org/10. 1016/j. jim. 2012. 05. 022.
15. Ferrara C, Bru P, Suter T, Moser S, Pu U, Uman P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous b1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II. Biotechnol Appl Biochem 2006; 93: 851-61.
16. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16: 1071-80; PMID: 22023369; http://dx. doi. org/10. 1111/j. 1365-2443. 2011. 01552. x.
17. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-40; PMID: 11986321; http://dx. doi. org/10. 1074/jbc. M202069200.
18. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73; PMID: 12427744; http://dx. doi. org/10. 1074/jbc. M210665200.
19. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21: 1644-52; PMID: 16321047; http://dx. doi. org/10. 1021/bp050228w.
20. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 2007; 104: 8433-7; PMID: 17485663; http://dx. doi. org/10. 1073/pnas. 0702936104.
21. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-3; PMID: 16888140; http://dx. doi. org/10. 1126/science. 1129594.
22. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-34; PMID: 17045339; http://dx. doi. org/10. 1016/j. molimm. 2006. 09. 005.
23. Anthony RM, Wermeling F, Karlsson MCI, Ravetch JV. Identification of a receptor required for the antiinflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571-8; PMID: 19036920; http://dx. doi. org/10. 1073/pnas. 0810163105.
24. Guhr T, Bloem J, Derksen NIL, Wuhrer M, Koenderman AHL, Aalberse RC, Rispens T. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PloS One 2011; 6: e21246; PMID: 21731683; http://dx. doi. org/10. 1371/journal. pone. 0021246.
25. Leontyev D, Katsman Y, Ma X-Z, Miescher S, Käsermann F, Branch DR. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52: 1799-1805; PMID: 22257295; http://dx. doi. org/10. 1111/j. 1537-2995. 2011. 03517.
26. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, Miescher S. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PloS one 2012; 7: e37243; http://dx. doi. org/10. 1371/journal. pone. 0037243.
27. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 2013; 425: 1253-8; PMID: 23416198; http://dx. doi. org/10. 1016/j. jmb. 2013. 02. 006.
28. Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song B-D, Higgins MK, Bowden Ta, Scanlan CN, Crispin M. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc 2013; 135: 9723-32; PMID: 23745692; http://dx. doi. org/10. 1021/ja4014375.
29. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW, Neschadim A, Leontyev D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol 2014; 192: 5031-8; PMID: 24760152; http://dx. doi. org/10. 4049/jimmunol. 1301611.
30. Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, Mourad W, Piccirillo CA, Mazer BD. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol 2014; 133: 853-63 e5; PMID: 24210883; http://dx. doi. org/10. 1016/j. jaci. 2013. 09. 029.
31. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie 2001; 83: 727-37; PMID: 11530204; http://dx. doi. org/10. 1016/S0300-9084(01)01301-3.
32. Dalziel M, McFarlane I, Axford JS. Lectin analysis of human immunoglobulin G N-glycan sialylation. Glycoconj J 1999; 16: 801-7; PMID: 11133020; http://dx. doi. org/10. 1023/A: 1007183915921.
33. Jassal R, Jenkins N, Charlwood J, Camilleri P, Jefferis R, Lund J. Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2, 6-sialyltransferase. Biochem Biophys Res Commun 2001; 286: 243-9; PMID: 11500028; http://dx. doi. org/10. 1006/bbrc. 2001. 5382.
34. Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res 2006; 5: 1792-802; PMID: 16823988; http://dx. doi. org/10. 1021/pr060034r.
35. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, James C, Ravetch JV. A recombinant IgG Fc that recapitulates the anti-inflammatory activity of IVIG. Science 2008; 320: 373-6; PMID: 18420934; http://dx. doi. org/10. 1126/science. 1154315.
36. Oaks M, Taylor S, Shaffer J. Autoantibodies targeting tumor-associated antigens in metastatic cancer: sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology 2013; 2: e24841; PMID: 23894724.
37. Stadlmann J, Pabst M, Altmann F. Analytical and functional aspects of antibody sialylation. J Clin Immunol 2010; 30: S15-S9; http://dx. doi. org/10. 1007/s10875-010-9409-2.
38. Raju TS, Briggs JB, Chamow SM, Winkler ME, Jones AJ. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 2001; 40: 8868-76; PMID: 11467948; http://dx. doi. org/10. 1021/bi010475i.
39. Barb AW, Brady EK, Prestegard JH. Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 2009; 48: 9705-7; PMID: 19772356; http://dx. doi. org/10. 1021/bi901430h.
40. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 1996; 157: 4963-9; PMID: 8943402.
41. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. Bio-Drugs 2011; 25: 1-11; PMID: 21033767; http://dx. doi. org/10. 2165/11537830-000000000-00000.
42. Rose RJ, van Berkel PHC, van den Bremer ETJ, Labrijn AF, Vink T, Schuurman J, Heck AJR, Parren PWHI. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. mAbs 2013; 5: 219-28; PMID: 23406897; http://dx. doi. org/10. 4161/mabs. 23532.
43. Lefranc M-P, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, et al. IMGTα, the international ImMunoGeneTics information system. Nucleic Acids Res 2009; 37: D1006-D12; PMID: 18978023; http://dx. doi. org/10. 1093/nar/gkn838.
44. Lee EU, Roth J, Paulson JC. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2, 6-sialyltransferase. J Biol Chem 1989; 264: 13848-55; PMID: 2668274.
45. Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999; 17: 1116-21; PMID: 10545921; http://dx. doi. org/10. 1038/15104.
46. Onitsuka M, Kim W-D, Ozaki H, Kawaguchi A, Honda K, Kajiura H, Fujiyama K, Asano R, Kumagai I, Ohtake H, et al. Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2, 6-sialyltransferase derived from Chinese hamster ovary cells. Appl Microbiol Biotechnol 2012; 94: 69-80; PMID: 22205442; http://dx. doi. org/10. 1007/s00253-011-3814-1.
47. Raymond C, Robotham A, Kelly J, Lattova E, Perreault H, Durocher Y. Production of highly sialylated monoclonal antibodies. In: Petrescu S, ed. Rijeka, Croatia: Intech; 2012.
48. Kumar N, Gammell P, Clynes M. Proliferation control strategies to improve productivity and survival during CHO based production culture: a summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines. Cytotechnology 2007; 53: 33-46; PMID: 19003188; http://dx. doi. org/10. 1007/s10616-007-9047-6.
49. Clark KJ-R, Griffiths J, Bailey KM, Harcum SW. Gene-expression profiles for five key glycosylation genes for galactose-fed CHO cells expressing recombinant IL-4/13 cytokine trap. Biotechnol Bioeng 2005; 90: 568-77; PMID: 15818560; http://dx. doi. org/10. 1002/bit. 20439.
50. Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol 2011; 7: 147-53; PMID: 21258329; http://dx. doi. org/10. 1038/nchembio. 511.
51. Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 2012; 51: 4618-26; PMID: 22574931; http://dx. doi. org/10. 1021/bi300319q.
52. Ramasamy V, Ramakrishnan B, Boeggeman E, Ratner DM, Seeberger PH, Qasba PK. Oligosaccharide preferences of beta1, 4-galactosyltransferase-I: crystal structures of Met340His mutant of human beta1, 4-galactosyltransferase-I with a pentasaccharide and trisaccharides of the N-glycan moiety. CA J Mol Biol 2005; 353: 53-67.
53. Weinstein J, de Souza-e-Silva U, Paulson JC. Sialylation of glycoprotein oligosaccharides N-linked to asparagine. J Biol Chem 1982; 257: 13845-53; PMID: 7142180.
54. Hossler P, Goh LT, Lee MM, Hu WS. GlycoVis: visualizing glycan distribution in the protein N-glycosylation pathway in mammalian cells. Biotechnol Bioeng 2006; 95: 946-60; PMID: 16807922; http://dx. doi. org/10. 1002/bit. 21062.
55. Blanken WM, van Vliet A, van den Eijnden DH. Branch specificity of bovine colostrum and calf thymus UDP-Gal: N-acetylglucosaminide beta-1, 4-galactosyltransferase. J Biol Chem 1984; 259: 15131-5; PMID: 6439717.
56. Paquet MR, Narasimhan S, Schachter H, Moscarello MA. Branch specificity of purified rat liver Golgi UDPgalactose: N-acetylglucosamine beta-1, 4-galactosyltransferase. Preferential transfer of galactose on the GlcNAc beta-1, 2-Man alpha-1, 3-branch of a complex biantennary Asn-linked oligosaccharide. J Biol Chem 1984; 259: 4716-21; PMID: 6425277.
57. Ramakrishnan B, Balaji PV, Qasba PK. Crystal structure of beta1, 4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol 2002; 318: 491-502; PMID: 12051854; http://dx. doi. org/10. 1016/S0022-2836(02)00020-7.
58. Hassinen A, Pujol FM, Kokkonen N, Pieters C, Kihlström M, Korhonen K, Kellokumpu S. Functional organization of Golgi N-and O-glycosylation pathways involves pH-dependent complex formation that is impaired in cancer cells. J Biol Chem 2011; 286: 38329-40; PMID: 21911486; http://dx. doi. org/10. 1074/jbc. M111. 277681.
59. Redpath S, Michaelsen TE, Sandlie I, Clark MR. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol 1998; 59: 720-7; PMID: 9796740; http://dx. doi. org/10. 1016/S0198-8859(98)00075-5.
60. Shi C, Shin YO, Hanson J, Cass B, Loewen MC, Durocher Y. Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells. Biochemistry 2005; 44: 15705-14; PMID: 16313173; http://dx. doi. org/10. 1021/bi051292p.
61. Zhang J, Liu X, Bell A, To R, Nath T, Azizi A, Li J, Cass B, Durocher Y. Transient expression and purification of chimeric heavy chain antibodies. Protein Expression Purif 2009; 65: 77-82; http://dx. doi. org/10. 1016/j. pep. 2008. 10. 011.
62. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30: E9; PMID: 11788735; http://dx. doi. org/10. 1093/nar/30. 2. e9.
63. Use of PEI for transfection may be covered by existing intellectual property rights iUP, 013, 240, European Patent 0, 770, 140, and foreign equivalents for which further information may be obtained by contacting licensing@polyplus-transfection. com.
64. Bigge JC, Patel TP, Bruce JA, Goulding PN, Charles SM, Parekh RB. Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal Biochem 1995; 230: 229-38; PMID: 7503412; http://dx. doi. org/10. 1006/abio. 1995. 1468.
65. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 1996; 240: 210-26; PMID: 8811911; http://dx. doi. org/10. 1006/abio. 1996. 0351.
66. Royle L, Radcliffe CM, Dwek RA, Rudd PM. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol 2006; 347: 125-43; PMID: 17072008.